Prognostic significance of BCL6 and KI67 in patients with chronic lymphocytic leukemia

Background Chronic lymphocytic leukemia (CLL) is a heterogeneous disease; its prognosis depends on the disease stage at diagnosis as well as the presence or absence of high-risk markers to determine the treatment strategy. Aim To evaluate the expression of BCL6 and Ki67 in patients with CLL and to a...

Full description

Saved in:
Bibliographic Details
Published in:The Egyptian journal of haematology : the official journal of the Egyptian Society of Haematology 2018-10, Vol.43 (4), p.179-183
Main Authors: Adel Elgammal, Maha, El-Halawani, Nabil, El-Sorady, Manal, El-Maghraby, Shereen, Sallam, Ghada
Format: Article
Language:English
Subjects:
B cells
Chronic lymphocytic leukemia
Gene expression
Genetic aspects
Lymphocytic leukemia
Medical research
Prognosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Chronic lymphocytic leukemia (CLL) is a heterogeneous disease; its prognosis depends on the disease stage at diagnosis as well as the presence or absence of high-risk markers to determine the treatment strategy. Aim To evaluate the expression of BCL6 and Ki67 in patients with CLL and to assess their clinical prognostic significance in relation to other established prognostic markers such as Zeta-associated protein of 70-Kd (ZAP70) and β2 microglobulin (β2M). Participants and methods BCL6 and Ki67 were measured using flow cytometry in thirty newly diagnosed CLL patients who presented to the Hematology units in Alexandria Main University Hospital and the Medical Research Institute, Alexandria University, they were also measured in 20 healthy age-matched and sex-matched controls. Results A statistically significant difference was found between cases and controls for both BCL6 and Ki67 expressions (P
ISSN:1110-1067
2090-9268
DOI:10.4103/ejh.ejh_26_18